Cargando…
Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers
Homozygous or compound heterozygous (biallelic) variants in PRKN are causal for PD with highly penetrant symptom expression, while the much more common heterozygous variants may predispose to PD with highly reduced penetrance, through altered mitochondrial function. In the presence of pathogenic het...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113363/ https://www.ncbi.nlm.nih.gov/pubmed/37072441 http://dx.doi.org/10.1038/s41531-023-00499-9 |
_version_ | 1785027823655714816 |
---|---|
author | Castelo Rueda, Maria Paulina Zanon, Alessandra Gilmozzi, Valentina Lavdas, Alexandros A. Raftopoulou, Athina Delcambre, Sylvie Del Greco M, Fabiola Klein, Christine Grünewald, Anne Pramstaller, Peter P. Hicks, Andrew A. Pichler, Irene |
author_facet | Castelo Rueda, Maria Paulina Zanon, Alessandra Gilmozzi, Valentina Lavdas, Alexandros A. Raftopoulou, Athina Delcambre, Sylvie Del Greco M, Fabiola Klein, Christine Grünewald, Anne Pramstaller, Peter P. Hicks, Andrew A. Pichler, Irene |
author_sort | Castelo Rueda, Maria Paulina |
collection | PubMed |
description | Homozygous or compound heterozygous (biallelic) variants in PRKN are causal for PD with highly penetrant symptom expression, while the much more common heterozygous variants may predispose to PD with highly reduced penetrance, through altered mitochondrial function. In the presence of pathogenic heterozygous variants, it is therefore important to test for mitochondrial alteration in cells derived from variant carriers to establish potential presymptomatic molecular markers. We generated lymphoblasts (LCLs) and human induced pluripotent stem cell (hiPSC)-derived neurons from non-manifesting heterozygous PRKN variant carriers and tested them for mitochondrial functionality. In LCLs, we detected hyperactive mitochondrial respiration, and, although milder compared to a biallelic PRKN-PD patient, hiPSC-derived neurons of non-manifesting heterozygous variant carriers also displayed several phenotypes of altered mitochondrial function. Overall, we identified molecular phenotypes that might be used to monitor heterozygous PRKN variant carriers during the prodromal phase. Such markers might also be useful to identify individuals at greater risk of eventual disease development and for testing potential mitochondrial function-based neuroprotective therapies before neurodegeneration advances. |
format | Online Article Text |
id | pubmed-10113363 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-101133632023-04-20 Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers Castelo Rueda, Maria Paulina Zanon, Alessandra Gilmozzi, Valentina Lavdas, Alexandros A. Raftopoulou, Athina Delcambre, Sylvie Del Greco M, Fabiola Klein, Christine Grünewald, Anne Pramstaller, Peter P. Hicks, Andrew A. Pichler, Irene NPJ Parkinsons Dis Article Homozygous or compound heterozygous (biallelic) variants in PRKN are causal for PD with highly penetrant symptom expression, while the much more common heterozygous variants may predispose to PD with highly reduced penetrance, through altered mitochondrial function. In the presence of pathogenic heterozygous variants, it is therefore important to test for mitochondrial alteration in cells derived from variant carriers to establish potential presymptomatic molecular markers. We generated lymphoblasts (LCLs) and human induced pluripotent stem cell (hiPSC)-derived neurons from non-manifesting heterozygous PRKN variant carriers and tested them for mitochondrial functionality. In LCLs, we detected hyperactive mitochondrial respiration, and, although milder compared to a biallelic PRKN-PD patient, hiPSC-derived neurons of non-manifesting heterozygous variant carriers also displayed several phenotypes of altered mitochondrial function. Overall, we identified molecular phenotypes that might be used to monitor heterozygous PRKN variant carriers during the prodromal phase. Such markers might also be useful to identify individuals at greater risk of eventual disease development and for testing potential mitochondrial function-based neuroprotective therapies before neurodegeneration advances. Nature Publishing Group UK 2023-04-18 /pmc/articles/PMC10113363/ /pubmed/37072441 http://dx.doi.org/10.1038/s41531-023-00499-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Castelo Rueda, Maria Paulina Zanon, Alessandra Gilmozzi, Valentina Lavdas, Alexandros A. Raftopoulou, Athina Delcambre, Sylvie Del Greco M, Fabiola Klein, Christine Grünewald, Anne Pramstaller, Peter P. Hicks, Andrew A. Pichler, Irene Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers |
title | Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers |
title_full | Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers |
title_fullStr | Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers |
title_full_unstemmed | Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers |
title_short | Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers |
title_sort | molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous prkn variant carriers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113363/ https://www.ncbi.nlm.nih.gov/pubmed/37072441 http://dx.doi.org/10.1038/s41531-023-00499-9 |
work_keys_str_mv | AT casteloruedamariapaulina molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers AT zanonalessandra molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers AT gilmozzivalentina molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers AT lavdasalexandrosa molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers AT raftopoulouathina molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers AT delcambresylvie molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers AT delgrecomfabiola molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers AT kleinchristine molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers AT grunewaldanne molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers AT pramstallerpeterp molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers AT hicksandrewa molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers AT pichlerirene molecularphenotypesofmitochondrialdysfunctioninclinicallynonmanifestingheterozygousprknvariantcarriers |